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BACKGROUND. Certain primary hepatic tumors have been associated with familial
adenomatous polyposis (FAP), a condition caused by germline mutations of the
adenomatous polyposis coli (APC) gene. However, a genetic association between
FAP and hepatocellular carcinoma (HCC) has not been shown. This study tested
the hypothesis that biallelic inactivation of the APC gene contributed to the
development of HCC in a patient with FAP and a known germline mutation of the
APC gene at codon 208, but no other risk factors for HCC.
METHODS. Total RNA and genomic DNA were isolated from the tumor, and in vitro
synthesized protein assay and DNA sequencing analysis were used to screen for a
somatic mutation in the APC gene.
RESULTS. A somatic one– base pair deletion at codon 568 was identified in the
wild-type allele of the APC gene.
CONCLUSIONS. To the authors’ knowledge, this study provides the first evidence
that biallelic inactivation of the APC gene may contribute to the development of
HCC in patients with FAP. Cancer 2001;92:332–9.
© 2001 American Cancer Society.
KEYWORDS: familial adenomatous polyposis, Gardner syndrome, adenomatous pol-
yposis coli (APC), loss of heterozygosity, hepatocellular carcinoma, in vitro synthe-
sized protein assay.
Familial adenomatous polyposis (FAP) is an autosomal dominantinherited disease characterized by the presence of numerous ad-
enomatous polyps throughout the colon and rectum. Polyps are usu-
ally clinically evident by the teen years. Progression of one or more
colonic adenomas often leads to colorectal carcinoma in patients with
FAP.1 Germline mutations in the adenomatous polyposis coli (APC)
gene have been found in many patients with FAP.2–5 In addition,
somatic mutations in the APC gene have been found in colorectal
tumors in patients with and without FAP.6 – 8 Almost all identified APC
mutations result in truncation of the APC protein. The APC protein
has been shown to function as a tumor suppressor by regulating the
transcriptional activity of b-catenin. APC protein promotes the deg-
radation of free b-catenin, a process that also involves axin and
glycogen synthase kinase 3b.9 –12 Colorectal tumors that do not have
APC mutations often express b-catenin mutants that are resistant to
regulation by APC.11,13
Patients with FAP can have extracolonic manifestations of their
disease.1 These include tumors of the upper gastrointestinal tract,
such as adenomas, microcarcinoids, and hyperplastic and lymphoid
polyps; osteomas of the mandible, skull, and long bones; and a variety
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of soft tissue lesions, including fibromas, lipomas, and
desmoid tumors. Familial adenomatous polyposis
that is associated with cutaneous and soft tissue le-
sions is referred to as Gardner syndrome;14 patients
with this syndrome are clinically but not genetically
different from others with FAP. Since the 1950s, a
variety of hepatic neoplasms have been described in
patients with FAP (see Table 1). Recently, biallelic
inactivation of the APC gene was described in one
hepatocellular adenoma15 and one hepatoblastoma.16
In the current study, we investigated the role of APC
mutation in the development of hepatocellular carci-
noma (HCC) in a patient with FAP. The patient had
clinical manifestations of Gardner syndrome and a
known germline mutation of the APC gene. To our
knowledge, this is the first report of a molecular anal-
ysis of the APC gene in a case of HCC that developed
in a patient with FAP.
MATERIALS AND METHODS
Clinical Summary
The family history of this patient has been reported
previously.17 This patient is the son of the proband
described in the earlier report. The patient had a
germline APC mutation that changed codon 208 from
coding for glutamine (CAG) to coding for a stop codon
(TAG; family MDA033 in Su et al.18). The patient re-
ceived a diagnosis of FAP in 1986 at age 15 and
underwent proctocolectomy in 1994. In 1996, he de-
veloped unresectable desmoid tumors in the periap-
pendiceal region and retroperitoneum that caused
right-sided hydronephrosis and necessitated ureteral
stenting. The patient was treated initially with tamox-
ifen and later with methotrexate and vinblastine; the
total duration of chemotherapy was less than 12
months. The growth of the desmoid tumors stabilized,
and the chemotherapy was discontinued. The patient
underwent routine computed tomography scanning
every 6 months.
In July 1999, a new hepatic mass measuring 5.8
3 4.4 cm was discovered on imaging, and the patient
was referred for consideration of hepatic resection. Stag-
ing evaluation revealed that the lesion was resectable
and that the patient had no extrahepatic disease except
for the known desmoids. The patient had no known risk
factors for HCC. The patient denied any alcohol abuse,
hepatitis B and C serology were negative, and carcino-
embryonic antigen and a-fetoprotein were within nor-
mal range. Endoscopy revealed tubular adenomas in the
duodenum but no other gastrointestinal manifestations
of FAP. The patient underwent an uncomplicated right
hepatic trisegmentectomy in February 2000. Pathologic
examination of the surgical specimen revealed a single,
well differentiated, encapsulated HCC without vascular
invasion (Fig. 1A). There was no underlying hepatitis,
fibrosis, or cirrhosis in the adjacent liver parenchyma
(Fig. 1B). At the time of this report, the patient had no
evidence of recurrent disease and had fully recovered
from the hepatic resection.
Molecular Analysis of the APC Gene
The patient gave informed consent for genetic analysis
of his tumor. The institutional review board approved
all sample collection and tumor analysis. The tumor
tissue was snap-frozen at the time of resection. Total
RNA was isolated from the tumor tissue using Trizol
reagent (Life Technologies, Gaithersburg, MD) and
used for the synthesis of the first strand cDNA by using
the SuperScript Preamplification system (Life Tech-
nologies) according to the manufacturer’s instruc-
tions. Genomic DNA was isolated from the tumor
tissue by proteinase K digestion followed by phenol-
chloroform extraction and ethanol precipitation. Total
RNA and genomic DNA isolated from blood of an
unrelated FAP patient were used as control samples in
this molecular analysis.
Various methods that are commonly used for
DNA mutation analysis have been used to detect APC
mutations. These methods include single-strand con-
formation polymorphism (SSCP),2 denature gradient
gel electrophoresis (DGGE),19 and RNase protection.5
These are effective methods to analyze small DNA
fragments, but inefficient for analysis of APC because
of the large coding region of this gene. After some
initial APC mutation analyses, it became obvious that
most if not all APC mutations resulted in truncation of
the APC protein (nonsense mutations, reading frame-
shift deletions or insertions). An efficient method for
analysis of the entire coding region of APC for trun-
cating mutations was developed independently by two
laboratories and has been called the in vitro synthe-
sized protein assay (IVSP) or protein truncation test
(PTT).20 –22 In addition to being a rapid method, IVSP
and PTT can detect genomic rearrangements that de-
lete exons or that result in splicing defects because
they can analyze cDNA instead of genomic DNA.18
These genomic rearrangements cannot be detected
using methods such as SSCP and DGGE that analyze
each exon individually. We used the IVSP to identify
potential somatic APC mutation in this case as we
have described previously.18 The coding region of APC
was amplified in three overlapping segments (segment
1, codons 1 to 811; segment 2, codons 680 to 1692; and
segment 3, codons 1547 to 2843). All polymerase chain
reactions (PCRs) were performed by using the Expand
Long Template PCR System (Boehringer Mannheim,
Indianapolis, IN) in the final volume of 25 mL as fol-
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lows: 1 cycle at 92 °C for 2 minutes; 35 cycles each at
92 °C for 15 seconds, 55 °C for 1 minute, and 68 °C for
2.5 minutes; and 1 cycle at 68 °C for 5 minutes. Seg-
ment 1 was amplified in two steps using cDNA as the
template. The first-step PCR used the upstream
primer 59-GGATCCTAATACGACTCACTATAGGGAGA-
CCACCATGGCTGCAGCTTCATATGATC-39 and the
downstream primer 59-ATAAGGCATAGAACATGTCC-
39. One microliter of the reaction product was used as
the template in the second-step PCR using the same
upstream primer and the downstream primer 59-CT-
GACCTATTATCATCATGTCG-39. Segments 2 and 3
were amplified using genomic DNA as the template.
The upstream primer 59-GGATCCTAATACGACTCAC-
TATAGGGAGACCACCATGGATGCATGTGGAACTTTG-
TGG-39 and the downstream primer 59-TTCTGTAG-
GAATGGTATCTCG-39 were used to amplify segment
2. The upstream primer 59-GGATCCTAATACGACT-
CACTATAGGGAGACCACCATGGAAAACCAAGAGAAA-
GAGGC-39 and the downstream primer 59-GAGTG-
GATCCCAAAATAAGACC-39 were used for the amplifi-
cation of segment 3. The coupled in vitro transcription
and translation reactions were performed in the pres-
ence of 35S-methionine by using the T7 TNT System
(Promega, Madison, WI). The products were resolved
on 10 –20%% gradient sodium dodecyl sulfate–poly-
acrylamide gels (Bio-Rad, Hercules, CA) and detected
by autoradiography using Kodak BioMax film (Roch-
ester, NY).
To determine the allele that carried the somatic
mutation, we cloned the PCR product of segment 1 by
using the Original TA Cloning Kit (Invitrogen, Carls-
bad, CA). Plasmid DNA was isolated from six clones.
The regions containing the germline mutation (codon
208) and the somatic mutation (codon 568) of each
clone were sequenced.
FIGURE 1. Hepatocellular carcinoma and surrounding normal hepatic parenchyma. (A) Hepatocellular carcinoma with trabecular and pseudoglandular pattern
composed of large, polygonal cells with abundant cytoplasm and nuclear pleomorphism (H & E stain original magnification 3160). (B) Adjoining nonneoplastic liver
showing focal macrovesicular steatosis but no fibrosis or cirrhosis (Masson’s Trichrome stain, original magnification 316).
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RESULTS
Mutation analysis of the APC gene in the HCC from
this patient confirmed the presence of the germline
mutation at codon 208 (Figs. 2A,B). No other mutant
IVSP product was apparent (Fig. 2 and data not
shown). However, in the tumor, the fast-migrating
IVSP product of segment 1 was as abundant as the
slower-migrating product (Fig. 2A). In contrast, the
control sample had less fast-migrating IVSP product of
segment 1 than the slower-migrating product. Our
previous study18 has shown that this finding indicates
a somatic mutation in segment 1 near exon 14. DNA
sequencing of segment 1 identified a one– base pair
deletion at codon 568 (AGT to GT; Fig. 2C). This mu-
tation was confirmed by sequencing APC exon 13 am-
plified using genomic DNA isolated from the tumor
(data not shown). This mutation was not found in the
same APC exon amplified using genomic DNA isolated
from adjacent normal liver (data not shown). To de-
termine whether the somatic mutation was present on
the germline wild-type allele of APC, the product of a
second reverse transcription–PCR of segment 1 was
cloned. Plasmid DNA was isolated from several indi-
vidual clones and sequenced. The result showed that
the somatic mutation and the germline mutation were
not on the same clone. Thus, the somatic mutation
was on the germline wild-type allele (Fig. 2D and data
not shown).
DISCUSSION
We found biallelic inactivation of the APC gene in a
HCC from a patient with Gardner syndrome. The pa-
FIGURE 2. Mutation analysis of APC. (A) Identification of APC mutation by IVSP. Only the result of segment 1 is shown. N and n indicate the slower-migrating
and faster-migrating normal products, respectively. The small arrow indicates the mutant product resulting from the germline mutation. The large arrowhead
indicates the increased intensity of the faster-migrating product. (B) Germline APC mutation. The arrow indicates the single nucleotide alteration that changed codon
208 from CAG (coding for glutamine) to TAG (stop codon). (C) Somatic APC mutation. Parts of the wild-type (top) and the mutant (bottom) sequences are shown
above the sequencing chromatogram. The arrow indicates the single base pair deletion. (D) Sequence of the somatic mutant APC allele. The arrow points to the
deletion (AA to A).
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tient had a germline APC mutation at codon 208, and
the tumor contained an additional somatic APC mu-
tation at codon 568 on the wild-type allele. The so-
matic APC mutation was not found in the surrounding
normal liver, and there were no clinical or pathologic
signs suggesting other risk factor for HCC. These find-
ings provide a genetic basis for the association be-
tween FAP and HCC and suggest a role for APC/b-
catenin pathway in the hepatic tumorigenesis of
patients with FAP.
b-Catenin performs at least two key functions in
cells.10 First, it plays a role in cell– cell adhesion. Sec-
ond, b-catenin, through interaction with Tcf/Lef, is a
signaling molecule involved in transcription and acti-
vation of target genes. The APC protein downregulates
b-catenin by promoting the degradation of free
b-catenin.23 As previously shown in colon carcinogen-
esis,9,11,13 disruption of normal APC/b-catenin func-
tions by mutation of the APC or b-catenin genes re-
sults in b-catenin accumulation in cells, leading to
upregulation of b-catenin target genes.
Patients with FAP have been shown to be at in-
creased risk for developing hepatic tumors. Hepato-
blastomas occur in young patients with FAP at least
100 times more often than in the general popula-
tion.24 –26 Biallelic mutation of the APC gene in a hepa-
toblastoma in a patient with a germline mutation of
APC16 and the existence of b-catenin mutations in
sporadic hepatoblastoma have been reported.27–29
Sporadic HCCs also have been found to contain
b-catenin mutation and accumulation.8,30 –33 Although
studies have examined the loss of heterozygosity at the
APC locus in HCC,34 our report is the first to our
knowledge to characterize a biallelic inactivation of
the APC gene in a HCC.
Note that our patient received a short course of
tamoxifen, a putative hepatocellular carcinogen, be-
fore the development of HCC. Tamoxifen-induced
DNA adduct formation in hepatocytes has been pro-
posed as a causative factor in the development of HCC
in selected rat strains, suggesting that differing genetic
susceptibility plays a role. Although two clinical re-
ports have described the association between the de-
velopment of HCC and tamoxifen in humans,35,36 hu-
mans are thought to be much less susceptible to
tamoxifen-induced DNA adduct formation than rats.37
Although tamoxifen currently is not considered to be a
primary hepatic carcinogen in humans, the possibility
of a role for tamoxifen in hepatocellular carcinogene-
sis among genetically susceptible patients remains.
This patient also received a short course of meth-
otrexate (cumulative dose ,1 g over 24 weeks). Long
courses of methotrexate for treatment of leukemia or
psoriasis have been associated with hepatic fibrosis,
and in rare cases hepatoma in a setting of “methotrex-
ate induced” hepatic fibrosis.38,39 These patients typ-
ically are treated for more than 5 years, with cumula-
tive methotrexate doses of 2.5 g in an 11-year-old girl38
and approximately 4 g in an adult.39 Certainly, the
association between methotrexate and hepatic fibrosis
is accepted, but the link to HCC is difficult to clarify
given that most cases occur as a second malignant
neoplasm in patients with existing cancers (particu-
larly acute leukemias, with recognized genetic de-
fects).40 Even in patients with prior HCC, risk for re-
currence or second primary HCC relates to existence
of underlying fibrosis,41 which was absent in this pa-
tient (Fig. 1B). Hutter et al.42 examined pathologic
specimens from livers of leukemic children before and
after the era of chemotherapy.42 They found that only
4% of leukemic children who did not receive chemo-
therapy had moderate hepatic fibrosis, and none had
severe fibrosis. Thirty-one percent of those who re-
ceived antifolate/steroid therapy and 42% of those
who received antipurine/anti-folate/steroid therapy
had moderate or severe hepatic fibrosis. None of the
273 patients was found to have HCC. Still, the survival
in chemotherapy group was more than double the
survival in the no chemotherapy group further cloud-
ing the analysis, and no such study could be repeated
given the current standard of care for leukemia.42
Given the tenuous relation between drug-induced
chronic liver disease and hepatocellular carcinoma
and the absence of definite fibrotic changes in the
underlying liver, methotrexate is unlikely to have con-
tributed to hepatocellular carcinoma in the current
study.
Many investigators have attempted to identify an
association between the location of germline APC mu-
tations and the occurrence of extracolonic manifesta-
tions of FAP. Desmoid tumors have been shown to
occur more frequently (though not always) when
germline mutations occur on the 39 half of the APC
gene.43– 45 The patient described in this report is one of
the exceptions; he developed desmoid tumors, but his
germline APC mutation was at the 59 end of APC (at
codon 208).
We reviewed all reported cases of hepatocellular
neoplasms in patients with FAP (Table 1). Germline
APC mutations have been identified in only a few of
these patients. There is no apparent correlation be-
tween the location of germline APC mutations and the
occurrence of these tumors. Giardiello and colleagues
described eight cases of hepatoblastoma in patients
with FAP and Gardner syndrome and found different
germline APC mutations between codons 141 and
1230.46 Bala and colleagues described a hepatocellular
adenoma in a patient with a germline APC mutation at
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codon 1451.15 Gruner and colleagues described a fi-
brolamellar variant of HCC in a patient with a germ-
line mutation in segment 3 of the APC gene, which
contains codons 1099 to 1693.47 The patient described
in our report had a germline mutation at APC codon
208. Further strengthening the hypothesis that the
patient in the current report was genetically suscepti-
ble to mutation is the negative study of Chen et al.48
These investigators examined hepatocellular carcino-
mas in 46 patients of whom 24 had cirrhosis and 43
had a history of hepatitis. They could show no loss of
heterozygosity of the APC or mutated in colorectal
carcinoma gene loci by fragment length polymor-
phism analysis or PCR and concluded that such a gene
defect in the genesis of HCC is likely very rare. Iden-
tification of a specific codon or set of codons that play
a role in HCC in FAP will be difficult given the low
incidence of the disease.
In summary, this study indicates that biallelic APC
inactivation may promote HCC or may lead to a ge-
netic instability in hepatocytes that, when combined
with other genetic or extraneous factors, leads to HCC.
Further study of germline and somatic APC mutations
and b-catenin pathway in FAP may help to unfold the
events leading to HCC in the subset of patients who
develop HCC in the absence of chronic liver disease.49
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